Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice

Podobne zapisy

• N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
  od: Baek, R, i wsp.
  Wydane: (2008)
• N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
  od: Baek, R, i wsp.
  Wydane: (2004)
• Substrate deprivation therapy reduces brain ganglioside content and GM1 in neonatal storage disease mice
  od: Kasperzyk, J, i wsp.
  Wydane: (2002)
• Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice
  od: J.L. Kasperzyk, i wsp.
  Wydane: (2005-04-01)
• "Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice" (vol 46, pg 744, 2004)
  od: Kasperzyk, J, i wsp.
  Wydane: (2005)